Skip to content
Biotechnology

Chiron AS Establishes State-of-the-Art Research Centre in Trondheim, Norway, Advancing Environmental Surveillance

ZeptoMetrix 2 mins read

TRONDHEIM, NORWAY / ACCESSWIRE / January 17, 2024 / Chiron AS, a leading producer of chemical reference materials headquartered in Trondheim, Norway, is pleased to announce the establishment of a state-of-the-art research centre dedicated to the enhanced surveillance of environmental pollutants.



This ground-breaking development, supported by an estimated 40 million NOK investment, reaffirms Chiron's commitment to advancing the field of environmental analysis.

The newly inaugurated research facility, which offers a 360-degree view of the Trondheim fjord, is equipped to address the most challenging pollutants of today, including microplastics and PFAS (commonly known as ‘forever chemicals'), and is poised to contribute significant research into environmental surveillance.

This strategic relocation follows Chiron's acquisition by Antylia Scientific in July 2023 and its successful incorporation into the ZeptoMetrix® Operating Division. The move to the new 1750 m2 premises aligns Chiron with Spex®, NSI Laboratories and High Purity Standards in strengthening the ZeptoMetrix Reference Material and Proficiency Testing portfolio.

"We are excited to embark on this journey of heightened environmental surveillance," Jon Eigill Johansen, Founder of Chiron AS, commented. "The establishment of our research centre highlights our commitment to scientific excellence. Through cutting-edge research and collaboration, we aim to support our mission to protect humans from undesired chemical exposure."

Evangeline Gonzalez, President of the ZeptoMetrix Operation Division, stated, "This investment reinforces our dedication to advancing environmental science. Chiron's state-of-the-art research centre adds a crucial dimension to the ZeptoMetrix portfolio. This means we are even more ready to support our lab and industry partners with critical innovation as they work to address ongoing environmental challenges."

About ZeptoMetrix®

ZeptoMetrix, an Antylia Scientific Company, is the industry leader and manufacturer for innovative solutions solving challenges in the evolving Diagnostic Microbiology Infectious Disease, Oncology market and Analytical Reference Materials for the Applied Markets. We focus on our customers' success by providing premium product quality, reliability, and expert technical knowledge, enabling our customers to develop and advance many applications across diagnostics, pharmaceutical, environmental, food and beverage industries. From in stock solutions to custom control and panel development through to launch, our scientific teams provide our customers with comprehensive, performance-oriented, and cost-effective products and services that positively impact the field of clinical diagnostics, analytical testing and contribute to a healthier world. ZeptoMetrix is an operating division of Antylia Scientific, a holding company of premier life science and diagnostic brands, including Cole-Parmer, Environmental Express and ZeptoMetrix.

Contact Information

Jennifer Button
Deputy Director
[email protected]
+44(0)7963508499

Related Files

Chiron AS Establishes State-of-the-Art Research Centre.pdf

SOURCE: Chiron AS

.

View the original press release on newswire.com.

More from this category

  • Biotechnology, Business Company News
  • 19/02/2026
  • 22:53
Ecopha Group Inc

Ecopha Group Inc. Recognised as One of the Most Innovative Companies to Watch in 2026 by The CEO Vision.

Key Facts: • Recognised by CEO Vision as one of the Most Innovative Companies to Watch in 2026• Incorporated in Delaware, USA in 2024…

  • Contains:
  • Biotechnology, Medical Health Aged Care
  • 19/02/2026
  • 12:50
Q-Sera

Improving laboratory management and patient outcomes – Q-Sera announces first product launch of its RAPClot(TM) rapid serum blood collection tube technology in Japan

Melbourne, Australia – February 19, 2026 – Q-Sera Pty Ltd, an Australian venture-backed company, today announced that leading Japanese medical device company, Terumo Corporation has launched VenoJect II RAPClotTM evacuated blood collection tubes in the Japanese market. These next-generation tubes incorporate Q-Sera’s patent protected technology and will improve laboratory management and patient outcomes. Even in anticoagulated blood, RAPClot™ rapid serum tubes rapidly produce high quality serum in five minutes. In the case of the VenoJect II RAPClot tubes, formulated to clot up to 6U/ml heparin. This is the first real innovation in the Japanese blood collection tube market in decades,…

  • Biotechnology, Business Company News
  • 12/02/2026
  • 12:22
Jane Morgan Management

BlinkLab Limited (ASX:BB1) Expands Pivotal FDA Trial Network to Nine Elite U.S. Sites Ahead of Imminent Study Commencement

12February 2026 – Sydney, Australia | BlinkLab Limited (ASX:BB1), a leader in AI-powered digital diagnostics, has expanded its U.S. clinical footprint with the onboarding…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.